Research progress on the biological regulatory function of lysophosphatidic acid in bone tissue cells

doi:10.7518/hxkq.2020.03.017

Abstract

Abstract:

Lysophosphatidic acid (LPA) is a small phospholipid that is present in all eukaryotic tissues and blood plasma. As an extracellular signaling molecule, LPA mediates many cellular functions by binding to six known G protein-coupled receptors and activating their downstream signaling pathways. These functions indicate that LPA may play important roles in many biological processes that include organismal development, wound healing, and carcinogenesis. Recently, many studies have found that LPA has various biological effects in different kinds of bone cells. These findings suggest that LPA is a potent regulator of bone development and remodeling and holds promising application potential in bone tissue engineering. Here, we review the recent progress on the biological regulatory function of LPA in bone tissue cells.

Key words: lysophosphatidic acid, osteoblast, osteoclast, osteocyte, bone tissue engineering

CLC Number:

Wu Xiangnan, Ma Yuanyuan, Hao Zhichao, Wang Hang. Research progress on the biological regulatory function of lysophosphatidic acid in bone tissue cells[J]. West China Journal of Stomatology, 2020, 38(3): 324-329.

References 53

[1]	Llona-Minguez S, Ghassemian A, Helleday T . Lysophosphatidic acid receptor (LPAR) modulators: the current pharmacological toolbox[J]. Prog Lipid Res, 2015,58:51-75.
[2]	Sheng XY, Yung YC, Chen A , et al. Lysophosphatidic acid signalling in development[J]. Development, 2015,142(8):1390-1395.
[3]	Kihara Y, Mizuno H, Chun J . Lysophospholipid receptors in drug discovery[J]. Exp Cell Res, 2015,333(2):171-177.
[4]	Choi JW, Herr DR, Noguchi K , et al. LPA receptors: subtypes and biological actions[J]. Annu Rev Pharmacol Toxicol, 2010,50(1):157-186. doi: 10.1146/annurev.pharmtox.010909.105753 URL
[5]	Dohi T, Miyauchi K, Ohkawa R , et al. Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome[J]. Atherosclerosis, 2013,229(1):192-197. doi: 10.1016/j.atherosclerosis.2013.03.038 URL
[6]	Santos-Nogueira E, López-Serrano C, Hernández J , et al. Activation of lysophosphatidic acid receptor type 1 contributes to pathophysiology of spinal cord injury[J]. J Neurosci, 2015,35(28):10224-10235. doi: 10.1523/JNEUROSCI.4703-14.2015 URL
[7]	Brindley DN, Lin FT, Tigyi GJ . Role of the autotaxin-lysophosphatidate axisin cancer resistance to chemotherapy and radiotherapy[J]. Biochim Biophys Acta, 2013,1831(1):74-85.
[8]	Fukushima N, Ishii S, Tsujiuchi T , et al. Comparative analyses of lysophosphatidic acid receptor-mediated signaling[J]. Cell Mol Life Sci, 2015,72(12):2377-2394.
[9]	Valdés-Rives SA, González-Arenas A . Autotaxin-lysophosphatidic acid: from inflammation to cancer development[J]. Mediators Inflamm, 2017,2017:9173090.
[10]	Mutoh T, Rivera R, Chun J . Insights into the pharmacological relevance of lysophospholipid receptors[J]. Br J Pharmacol, 2012,165(4):829-844. doi: 10.1111/j.1476-5381.2011.01622.x URL
[11]	Lai YJ, Lin WC, Lin FT . PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration[J]. J Biol Chem, 2007,282(33):24381-24387.
[12]	Ishii I, Contos JJ, Fukushima N , et al. Functional comparisons of the lysophosphatidic acid receptors, LPA1/VZG-1/EDG-2, LPA2/EDG-4, and LPA3/EDG7 in neuronal cell lines using a retrovirus expression system[J]. Mol Pharmacol, 2000,58(5):895-902.
[13]	Lai SL, Yao WL, Tsao KC , et al. Autotaxin/Lpar3 signaling regulates Kupffer’s vesicle formation and left-right asymmetry in zebrafish[J]. Development, 2012,139(23):4439-4448. doi: 10.1242/dev.081745 URL
[14]	Lee CW, Rivera R, Dubin AE , et al. LPA4/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing gs-, Gq/Gi-mediated calcium signaling and G12/13-mediated rho activation[J]. J Biol Chem, 2007,282(7):4310-4317. doi: 10.1074/jbc.M610826200 URL
[15]	Yanagida K, Kurikawa Y, Shimizu T , et al. Current progress in non-Edg family LPA receptor research[J]. Biochim Biophys Acta, 2013,1831(1):33-41.
[16]	Taniguchi R, Inoue A, Sayama M , et al. Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6[J]. Nature, 2017,548(7667):356-360.
[17]	Yanagida K, Masago K, Nakanishi H , et al. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6[J]. J Biol Chem, 2009,284(26):17731-17741.
[18]	Lee M, Choi S, Halldén G , et al. P2Y5 is a Gαi, Gα12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion[J]. Am J Physiol Gastrointest Liver Physiol, 2009,297(4):G641-G654. doi: 10.1152/ajpgi.00191.2009 URL
[19]	Infante A, Rodríguez CI . Osteogenesis and aging: lessons from mesenchymal stem cells[J]. Stem Cell Res Ther, 2018,9(1):244. doi: 10.1186/s13287-018-0995-x URL
[20]	Lee MJ, Jeon ES, Lee JS , et al. Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells[J]. J Cell Biochem, 2008,104(2):499-510. doi: 10.1002/(ISSN)1097-4644 URL
[21]	Liu YB, Kharode Y, Bodine PV , et al. LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4[J]. J Cell Biochem, 2010,109(4):794-800.
[22]	Mansell JP, Nowghani M, Pabbruwe M , et al. Lysophosphatidic acid and calcitriol co-operate to promote human osteoblastogenesis: requirement of albumin-bound LPA[J]. Prostagland Other Lipid Mediat, 2011,95(1/2/3/4):45-52. doi: 10.1016/j.prostaglandins.2011.05.003 URL
[23]	Chen Z, Luo Q, Lin C , et al. Simulated microgravity inhibits osteogenic differentiation of mesenchymal stem cells via depolymerizing F-actin to impede TAZ nuclear translocation[J]. Sci Rep, 2016,6:30322.
[24]	Chen JH, Baydoun AR, Xu RX , et al. Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis[J]. Stem Cells, 2008,26(1):135-145. doi: 10.1634/stemcells.2007-0098 URL
[25]	Wang XY, Fan XS, Cai L , et al. Lysophosphatidic acid rescues bone mesenchymal stem cells from hydrogen peroxide-induced apoptosis[J]. Apoptosis, 2015,20(3):273-284.
[26]	Sims SM, Panupinthu N, Lapierre DM , et al. Lysophosphatidic acid: a potential mediator of osteoblast-osteoclast signaling in bone[J]. Biochim Biophys Acta, 2013,1831(1):109-116.
[27]	Lancaster S, Mansell JP . The role of lysophosphatidic acid on human osteoblast formation, maturation and the implications for bone health and disease[J]. Clin Lipidol, 2013,8(1):123-135. doi: 10.2217/CLP.12.86 URL
[28]	Caverzasio J, Palmer G, Suzuki A , et al. Evidence for the involvement of two pathways in activation of extracellular signal-regulated kinase (erk) and cell proliferation by Gi and Gq protein-coupled receptors in osteoblast-like cells[J]. J Bone Miner Res, 2000,15(9):1697-1706. doi: 10.1359/jbmr.2000.15.9.1697 URL
[29]	Grey A, Banovic T, Naot D , et al. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve Gi proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases[J]. Endocrinology, 2001,142(3):1098-1106. doi: 10.1210/endo.142.3.8011 URL
[30]	Grey A, Chen Q, Callon K , et al. The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving Gi proteins and phosphatidylinositol-3 kinase[J]. Endocrinology, 2002,143(12):4755-4763. doi: 10.1210/en.2002-220347 URL
[31]	Yao SC, Zhang YN, Wang XY , et al. Pigment epithelium-derived factor (PEDF) protects osteoblastic cell line from glucocorticoid-induced apoptosis via PEDF-R[J]. Int J Mol Sci, 2016,17(5):730.
[32]	Lee H, Goetzl EJ, An SZ . Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing[J]. Am J Physiol Cell Physiol, 2000,278(3):C612-C618.
[33]	Masiello LM, Fotos JS, Galileo DS , et al. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells[J]. Bone, 2006,39(1):72-82.
[34]	Karagiosis SA, Chrisler WB, Bollinger N , et al. Lysophosphatidic acid-induced ERK activation and chemotaxis in MC3T3-E1 preosteoblasts are independent of EGF receptor transactivation[J]. J Cell Physiol, 2009,219(3):716-723. doi: 10.1002/jcp.v219:3 URL
[35]	Panupinthu N, Zhao L, Possmayer F , et al. P2X7 nucleotide receptors mediate blebbing in osteoblasts through a pathway involving lysophosphatidic acid[J]. J Biol Chem, 2007,282(5):3403-3412. doi: 10.1074/jbc.M605620200 URL
[36]	Gidley J, Openshaw S, Pring ET , et al. Lysophosphatidic acid cooperates with 1α,25(OH)₂D₃ in stimulating human MG63 osteoblast maturation[J]. Prostagland Other Lipid Mediat, 2006,80(1/2):46-61. doi: 10.1016/j.prostaglandins.2006.04.001 URL
[37]	Mansell JP, Farrar D, Jones S , et al. Cytoskeletal reorganisation, 1α,25-dihydroxy vitamin D3 and human MG63 osteoblast maturation[J]. Prostagland Other Lipid Mediat, 2009,305(1/2):38-46.
[38]	Hong L, Sharp T, Khorsand B , et al. Correction: microRNA-200c represses IL-6, IL-8, and CCL-5 expression and enhances osteogenic differentiation[J]. PLoS One, 2016,11(12):e0169381. doi: 10.1371/journal.pone.0169381 URL
[39]	Niu X, Chen YM, Qi L , et al. Hypoxia regulates angeogenic-osteogenic coupling process via up-regulating IL-6 and IL-8 in human osteoblastic cells through hypoxia-inducible factor-1α pathway[J]. Cytokine, 2019,113:117-127.
[40]	Aki Y, Kondo A, Nakamura H , et al. Lysophosphatidic acid-stimulated interleukin-6 and -8 synjournal through LPA1 receptors on human osteoblasts[J]. Arch Oral Biol, 2008,53(3):207-213. doi: 10.1016/j.archoralbio.2007.08.006 URL
[41]	Yu ZL, Li DQ, Huang XY , et al. Lysophosphatidic acid upregulates connective tissue growth factor expression in osteoblasts through the GPCR/PKC and PKA pathways[J]. Int J Mol Med, 2016,37(2):468-474. doi: 10.3892/ijmm.2016.2450 URL
[42]	Appelman-Dijkstra NM, Papapoulos SE . Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway[J]. Nat Rev Endocrinol, 2018,14(10):605-623.
[43]	Karagiosis SA, Karin NJ . Lysophosphatidic acid induces osteocyte dendrite outgrowth[J]. Biochem Biophys Res Commun, 2007,357(1):194-199.
[44]	Waters KM, Jacobs JM, Gritsenko MA , et al. Regulation of gene expression and subcellular protein distribution in MLO-Y4 osteocytic cells by lysophosphatidic acid: relevance to dendrite outgrowth[J]. Bone, 2011,48(6):1328-1335. doi: 10.1016/j.bone.2011.02.020 URL
[45]	Boyce BF, Li JB, Xing LP , et al. Bone remodeling and the role of TRAF3 in osteoclastic bone resorption[J]. Front Immunol, 2018,9:2263. doi: 10.3389/fimmu.2018.02263 URL
[46]	David M, Wannecq E, Descotes F , et al. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts[J]. PLoS One, 2010,5(3):e9741.
[47]	David M, Machuca-Gayet I, Kikuta J , et al. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity[J]. J Biol Chem, 2014,289(10):6551-6564.
[48]	Orosa B, García S, Martínez P , et al. Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis[J]. Ann Rheum Dis, 2014,73(1):298-305.
[49]	Lapierre DM, Tanabe N, Pereverzev A , et al. Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival[J]. J Biol Chem, 2010,285(33):25792-25801. doi: 10.1074/jbc.M110.109322 URL
[50]	McMichael BK, Meyer SM, Lee BS . C-src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation[J]. J Biol Chem, 2010,285(34):26641-26651. doi: 10.1074/jbc.M110.119909 URL
[51]	Mansell JP, Barbour M, Moore C , et al. The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces[J]. Biomaterials, 2010,31(2):199-206. doi: 10.1016/j.biomaterials.2009.09.035 URL
[52]	Bosetti M, Borrone A, Leigheb M , et al. Injectable graft substitute active on bone tissue regeneration[J]. Tissue Eng Part A, 2017,23(23/24):1413-1422.
[53]	Binder BY, Williams PA, Silva EA , et al. Lysophosphatidic acid and sphingosine-1-phosphate: a concise review of biological function and applications for tissue engineering[J]. Tissue Eng Part B Rev, 2015,21(6):531-542.